| Ytd | 88.88% | |
| 1y | 98.24% |
| Open | 51.92 | Prev Close | 51.72 | Low | 51.25 | High | 53.04 | Mkt Cap | 8.81B |
| Vol | 1.15M | Avg Vol | 2.21M | EPS | 0.95 | P/E | 55.63 | Forward P/E | 31.72 |
| Beta | 0.34 | Short Ratio | 6.33 | Inst. Own | 110.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 45.50 | 200-d Avg | 34.71 | 1yr Est | 50.56 |
ALKS News
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings bea
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target
Alkermes reports positive long-term data for alixorexton, showing sustained wakefulness and symptom
Alkermes plc (NASDAQ:ALKS) today announced results from a planned interim analysis of the ongoing lo
On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal
Mizuho analyst Uy Ear maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price tar
Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raise
Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad
B of A Securities analyst Jason Gerberry downgrades Alkermes (NASDAQ:ALKS) from Neutral to Underp
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target
TD Cowen analyst Joseph Thome maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price ta
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings
Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Monday